Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

INTRODUCTION: Our preclinical work suggests that low-dose angiogenesis inhibition could potentiate programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade. In a cohort of our multicenter phase 1b and 2 study (NCT03083041), promising antitumor activity was observed with camreli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Shengxiang, He, Jianxing, Fang, Yong, Chen, Gongyan, Ma, Zhiyong, Chen, Jianhua, Guo, Renhua, Lin, Xiaoyan, Yao, Yu, Wu, Gang, Wang, Quanren, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046448/
https://www.ncbi.nlm.nih.gov/pubmed/35498381
http://dx.doi.org/10.1016/j.jtocrr.2022.100312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046448/
https://www.ncbi.nlm.nih.gov/pubmed/35498381
http://dx.doi.org/10.1016/j.jtocrr.2022.100312

Ejemplares similares